Mental illness is systematically overdiagnosed to sell pharmaceuticals

The claim

American psychiatry has been captured by the pharmaceutical industry. What once required genuine clinical impairment to diagnose — depression, anxiety, ADHD — has been progressively redefined by DSM revisions that lower thresholds, manufacture new categories, and expand the market for drugs. The result is a nation of over-medicated patients who have been told that ordinary grief, distraction, and sadness are medical conditions requiring lifelong pharmaceutical management. Robert Whitaker’s Anatomy of an Epidemic (2010) gave this critique its most influential popular form: that rising rates of psychiatric disability, paradoxically, followed rather than preceded the mass prescription of psychiatric medications, suggesting the drugs themselves may be causing long-term harm. The pharmaceutical industry’s grip on clinical trial publication, continuing medical education, and the DSM revision process has, on this account, corrupted psychiatry’s scientific foundations.

The mechanism

The overdiagnosis critique rests on three interlocking mechanisms: (1) DSM diagnostic expansion lowering thresholds and adding categories, increasing the denominator of diagnosable people; (2) publication bias systematically inflating apparent drug efficacy in the literature; and (3) financial conflicts of interest among the psychiatrists who set both diagnostic criteria and treatment guidelines. Each mechanism is real. The contested question is whether together they constitute evidence that the underlying conditions are manufactured rather than undertreated.

DSM expansion: DSM-III (1980) introduced operationalized, symptom-checklist criteria — a genuine scientific improvement over psychoanalytic vagueness, but one that set a ratchet in motion. Each subsequent edition has added categories (DSM-5 includes disruptive mood dysregulation disorder, hoarding disorder, and premenstrual dysphoric disorder) and shortened required symptom durations. The bereavement exclusion for major depression — which prevented diagnosing grief as illness for two months after a loss — was removed in DSM-5 over substantial internal opposition. Allen Frances, who chaired the DSM-IV task force, wrote Saving Normal (2013) arguing that DSM-5 would pathologize ordinary human experience. This is not a fringe critique; it came from psychiatry’s own establishment.

Publication bias: Turner et al.’s landmark 2008 analysis in the New England Journal of Medicine registered every antidepressant trial submitted to the FDA for approval between 1987 and 2004. Of 74 trials, 38 had positive results; 37 of those 38 were published. Of 36 negative or ambiguous trials, 22 were not published at all, and 11 were published in ways that characterized the results as positive. The net effect was a published literature that made antidepressants appear 32% more effective than the complete evidence base warranted. This is not a small distortion. It shaped two decades of prescribing guidelines.

Kirsch and the placebo question: Irving Kirsch’s 2008 PLOS Medicine meta-analysis used Freedom of Information Act requests to obtain the same FDA trial data and found that the mean drug–placebo difference on the Hamilton Rating Scale was 1.80 points — below the 3-point threshold the UK’s National Institute for Health and Care Excellence uses as a marker of clinical significance. The media coverage of this finding (“antidepressants don’t work”) was substantially oversimplified: the effect was below clinical significance for mild-to-moderate depression but exceeded it for patients with Hamilton scores above 25, indicating severe depression. The qualified finding — that antidepressants are most beneficial for the most severely ill — is important, but it does not support the strong overdiagnosis claim that the drugs are broadly ineffective.

ADHD diagnostic geography: If ADHD prevalence were primarily genetic and neurobiological, it should not vary threefold between US states or between the US (10.2% of children) and France (3.5%) or Germany (2.2%), given comparable population genetics. Visser et al. (2014) documented state-level variation from roughly 6% to 16% that correlates with insurance coverage rules, school policies, and availability of non-pharmaceutical alternatives. Cultural and system factors are clearly shaping diagnosis rates, though this does not mean ADHD as a neurobiological construct is invalid.

The evidence

Where the critique is well-supported: The financial entanglement between pharmaceutical manufacturers and psychiatry’s leadership is extensively documented. Cosgrove et al. (2006) found that 56% of DSM-IV panel members had at least one financial relationship with the pharmaceutical industry; for panels covering diagnostic areas directly linked to marketed drugs, the figure was 100%. The panel members who revised mood disorder and schizophrenia criteria had the highest rates of industry ties — the categories with the largest drug markets. This is a documented conflict of interest in the construction of the diagnostic canon, not a conspiracy theory.

Whitaker’s Anatomy of an Epidemic raised a specific and empirically testable claim: that rates of psychiatric disability (measured by Social Security Disability Insurance enrollment for mental disorders) rose in parallel with rising prescription rates. SSDI enrollment for mental disorders did rise from approximately 1.25 million in 1987 to over 4 million by the mid-2000s. The question is causation: are people on disability because psychiatric medications fail them, or because the same social and economic forces that generate mental illness also generate disability? Case and Deaton’s deaths-of-despair research strongly implicates the latter — deindustrialization, declining wages, and social fragmentation are primary drivers of the mortality and disability rise among non-college-educated whites, not iatrogenic pharmaceutical harm.

Where the critique is overstated: Cipriani et al.’s 2018 Lancet meta-analysis of 522 randomized controlled trials covering 116,477 participants found that all 21 antidepressants studied were more effective than placebo, with response rate ratios ranging from 1.37 to 1.96. This was the largest and most comprehensive synthesis of antidepressant evidence ever conducted and found consistent, if variable, efficacy. The effect sizes are modest for mild presentations — consistent with Kirsch — but the claim that antidepressants broadly “don’t work” is not supported by the full evidence base.

The WHO’s 2022 World Mental Health Report documents a global treatment gap that is the opposite of overdiagnosis: 75% of people with mental health conditions in low- and middle-income countries receive no treatment at all. Even in high-income countries, SAMHSA’s 2022 NSDUH found that of approximately 59 million US adults with any mental illness, only about 26 million received any mental health treatment — a treatment rate below 50%. If pharmaceutical marketing had truly saturated the diagnostic and prescribing landscape, the treatment gap would not be this large.

The genuine substrate: Case and Deaton’s deaths-of-despair research (Mortality and Morbidity in the 21st Century, Brookings, 2017) documents that the rise in suicide, drug overdose, and alcohol-related mortality among middle-aged white Americans without college degrees tracks deindustrialization and economic precarity with high specificity. This is not manufactured distress. The opioid epidemic itself followed a pharmaceutical marketing strategy (Purdue Pharma’s OxyContin campaign) that was directly analogous to what the overdiagnosis critics describe for psychiatry — yet no one concludes that addiction is not a real condition. The pharmaceutical corruption and the genuine suffering are both real simultaneously.

Cross-national ADHD comparison: The Netherlands (2.2%) and France (3.5%) diagnose ADHD at roughly one-fifth the US rate (10.2%). German clinical guidelines emphasize multimodal assessment and require behavioral intervention before medication. The French child psychiatric tradition historically resisted categorical diagnosis in favor of psychodynamic formulation. These differences appear to reflect genuine diagnostic and treatment system differences, not underlying prevalence differences. The implication is not that ADHD does not exist, but that US diagnosis and medication rates have outrun the evidence base for pharmacological intervention in mild-to-moderate cases.

Who benefits

Pharmaceutical manufacturers of antidepressants (SSRIs, SNRIs) and stimulants (amphetamine salts, methylphenidate) have the clearest financial stake in diagnostic expansion. The global antidepressant market was valued at approximately $15.5 billion in 2022. AbbVie, Eli Lilly, Pfizer, and Johnson & Johnson have collectively paid billions in settlements for off-label marketing, suppressed trial data, and kickbacks to prescribers. The publication bias documented by Turner et al. (2008) was not accidental — pharmaceutical sponsors have financial control over whether trials are submitted for publication.

Psychiatrists with pharmaceutical industry ties benefit from continuing medical education funding, speaker bureau fees, and consulting contracts. Cosgrove and Krimsky (2012) found that industry relationships are concentrated among the highest-profile academic psychiatrists — those most likely to influence prescribing guidelines and training programs.

The overdiagnosis critique is also instrumentalized by opponents of mental health parity. Insurance companies and employer self-insurance plans that resist covering mental health services equivalent to physical health services sometimes invoke the over-medicalization concern to resist parity enforcement. The logic is circular: if mental health conditions are not real diseases, parity requirements are category errors. This use of the critique is opportunistic and not supported by the preponderance of evidence.

The counter

The overdiagnosis critique deserves more respect than mainstream psychiatry has given it. The DSM is a committee product shaped by professional and commercial interests, not a validated biological taxonomy. The low inter-rater reliability of many diagnoses (kappa values for depression and ADHD in routine clinical settings are substantially lower than in research trials) means that diagnostic thresholds are genuinely uncertain, not scientifically fixed. Whitaker’s challenge to psychiatry’s triumphalist narrative — that biological psychiatry had solved problems that psychosocial approaches could not — was warranted. The evidence that long-term antipsychotic use can produce dopamine supersensitivity and worsen long-term outcomes for some patients is real, even if the magnitude is contested.

The moderate, defensible version of the overdiagnosis thesis: pharmaceutical marketing has shifted prescribing toward pharmacological first-line treatments for conditions where evidence supports psychotherapy as equally or more effective (cognitive behavioral therapy for mild-to-moderate depression; behavioral intervention for ADHD in young children); this has occurred in a diagnostic landscape where thresholds have been lowered by committees with conflicts of interest. This is a reform agenda for psychiatry and its relationship to the pharmaceutical industry, not evidence that mental illness is primarily manufactured.

References

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7

Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 75(3), 154–160. https://doi.org/10.1159/000091772

Frances, A. (2013). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. William Morrow.

Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine, 5(2), e45. https://doi.org/10.1371/journal.pmed.0050045

Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 national survey on drug use and health (HHS Publication No. PEP23-07-01-006). SAMHSA. https://www.samhsa.gov/data/report/2022-nsduh-annual-national-report

Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358(3), 252–260. https://doi.org/10.1056/NEJMsa065779

Visser, S. N., Danielson, M. L., Bitsko, R. H., Holbrook, J. R., Kogan, M. D., Ghandour, R. M., Perou, R., & Blumberg, S. J. (2014). Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. Journal of the American Academy of Child & Adolescent Psychiatry, 53(1), 34–46. https://doi.org/10.1016/j.jaac.2013.09.001

Whitaker, R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. Crown Publishers.

World Health Organization. (2022). World mental health report: Transforming mental health for all. WHO Press. https://www.who.int/publications/i/item/9789240049338

Case, A., & Deaton, A. (2017). Mortality and morbidity in the 21st century. Brookings Papers on Economic Activity, Spring 2017, 397–476. https://doi.org/10.1353/eca.2017.0005